scholarly journals An Evaluation of the Effect of Various Concentrations of the Clemson University Pasteurella multocida Drinking Water Vaccine on the Immune Response Against Fowl Cholera Disease in Turkeys

1977 ◽  
Vol 56 (1) ◽  
pp. 327-330 ◽  
Author(s):  
B.W. Bierer
2013 ◽  
Vol 2 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Samina Ievy ◽  
Mohammad Ferdousur Rahman Khan ◽  
Md Ariful Islam ◽  
Md Bahanur Rahman

The research work was performed for the isolation and identification of Pasteurella multocida from field cases, preparation of oil adjuvanted vaccine from isolated strain and determination of its efficacy. Samples were collected from suspected dead birds of three poultry farms of Bangladesh (Code name: M and R). The P. multocida isolates were Gram negative, non-motile, non- spore forming rod occurring singly or pairs and occasionally as chains or filaments. Biochemically P. multocida ferment basic sugar and consistently produced acid except from maltose and lactose. After isolation formalin killed oil adjuvanted Fowl cholera vaccine was prepared in Laboratory of the Department of Microbiology and Hygiene, BAU and this experimental vaccine (3.2x108 CFU/ml) was administered in nine weeks old White Leg Horn chickens at the different dose rate through intramuscular (IM) route in each selected group A (1ml alum precipitated vaccine), B (0.5ml alum precipitated vaccine), C (1ml oil adjuvanted vaccine) and D (0.5ml oil adjuvanted vaccine). Pre-vaccinated sera were collected from all groups of birds. The mean of Passive Hemagglutination (PHA) titers of post-vaccination were 51±17.8, 76.8±17, 89.6±17, and 115±17.81 in group A, B, C and D respectively which consist of 5 birds in each. The vaccine produced better immune response when boostering with the similar dose and route at 15 days after primary vaccination. The mean PHA titers were higher at group D than other groups after boostering. Challenge infection was conducted on all the vaccinated and control group (n=5) of birds after 15 days of vaccination which protect 93.75% of birds and the PHA titers from different groups analyzed to determine the protective capacity of vaccinated chickens against challenge exposure. It was demonstrated that experimental oil adjuvanted fowl cholera vaccine with 0.5ml dose produce higher immune response against challenge infection and found to be safe. Microbes and Health, June 2013, 2(1): 1-4DOI: http://dx.doi.org/10.3329/mh.v2i1.17253


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Rine Christopher Reuben ◽  
Shovon Lal Sarkar ◽  
Habiba Ibnat ◽  
Md. Ali Ahasan Setu ◽  
Pravas Chandra Roy ◽  
...  

AbstractPasteurella multocida causes fowl cholera, a highly contagious poultry disease of global concern, causing significant ecological and economic challenges to the poultry industry each year. This study evaluated the effects of novel multi-strain probiotics consisting of Lactobacillus plantarum, L. fermentum, Pediococcus acidilactici, Enterococcus faecium and Saccharomyces cerevisiae on growth performance, intestinal microbiota, haemato-biochemical parameters and anti-inflammatory properties on broilers experimentally challenged with P. multocida. A total of 120 birds were fed with a basal diet supplemented with probiotics (108 CFU/kg) and then orally challenged with 108 CFU/mL of P. multocida. Probiotics supplementation significantly (P < 0.05) improved growth performance and feed efficiency as well as reducing (P < 0.05) the population of intestinal P. multocida, enterobacteria, and mortality. Haemato-biochemical parameters including total cholesterol, white blood cells (WBC), proteins, glucose, packed cell volume (PCV) and lymphocytes improved (P < 0.05) among probiotic fed birds when compared with the controls. Transcriptional profiles of anti-inflammatory genes including hypoxia inducible factor 1 alpha (HIF1A), tumor necrosis factor- (TNF) stimulated gene-6 (TSG-6) and prostaglandin E receptor 2 (PTGER2) in the intestinal mucosa were upregulated (P < 0.05) in probiotics fed birds. The dietary inclusion of the novel multi-strain probiotics improves growth performance, feed efficiency and intestinal health while attenuating inflammatory reaction, clinical signs and mortality associated with P. multocida infection in broilers.


Author(s):  
Teferi Mandado

This paper was done starting from February 2017 to July 2017 in Jimma University College of Agriculture and School of Veterinary Medicine. The suffering of different animal species from multiple infectious agents in and around the university leads us to be conscious and enabled us to write this scientific paper which can be acts as the source of information for Veterinary vaccinology. Louis Pasteur in the 19th century demonstrated the ability to protect chickens against fowl cholera (Pasteurella multocida) and thus demonstrated the benefit of vaccination in animals and paved the way for the development of the array of veterinary vaccines which are in use today. Since Pasteur’s work, vaccination against infectious disease have been used successfully to protect animals from many serious diseases some of which were also significant risks to humans. Veterinary vaccine has a parallel way of development in research and development of vaccines in the human field vaccinology today also. Vaccine is a biological preparation that improves immunity to a particular disease. Vaccine contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe or its toxins. The general information concerning veterinary vaccination such as common vaccination, common methods of veterinary vaccination, principles of vaccination; standardization of veterinary vaccines, generation of vaccine, vaccine formulation, new approaches to veterinary vaccines and few other information were roughly reviewed from scientific journals, experiment results, proceedings, reference books and manuals. The objectives of this paper are to highlight the general current information of Veterinary Vaccinology and to give specific recommendations based on the facts obtained.


2018 ◽  
Vol 15 (2) ◽  
pp. 91-95
Author(s):  
M. R. Hossain ◽  
M. M. Meher ◽  
M. Afrin

The present study was undertaken to determine the present status of fowl cholera (FC) infection of poultry in Gazipur district during September 2016 to February 2017. A total of 282 either dead or sick birds (Layer and Sonali) were taken as sample in which the sick birds were subjected to record clinical data and consequently the dead birds were for post mortem examination. Hence, overall 12.41% prevalence was found for FC and about 87.59% was for mixed other diseases.  All the birds were grouped into six named as A1, A2 and up to A6 accordingly their age. The highest incidence (29.79 %) was found in A1 (8-20weeks) group and the lowest was 4.26% in A5 (51-60 weeks) group. Furthermore, six FC infected farms were categorized to treat with six specific antibiotics individually. Thereafter, the highest recovery rate (89.6% and 87.5%) was recorded in two farms using Enrofloxacin and Gentamicin particularly. The lowest recovery rate (60%) was in Erythromycin treatment group. However, the layer birds of six farms lost their body weight almost 11.84%, specifically the highest percentages (16.49%) was in treated with Ampicillin and lowest percentages (5.79%) found in a farm treated with Gentamicin. In brief, FC commonly appears just near to laying age and therapeutic management trivially decreases the body weight that ultimately shoots up the production cost.


2010 ◽  
Vol 78 (9) ◽  
pp. 3669-3677 ◽  
Author(s):  
Marina Harper ◽  
Andrew D. Cox ◽  
Frank St. Michael ◽  
Mark Ford ◽  
Ian W. Wilkie ◽  
...  

ABSTRACT Pasteurella multocida is the causative agent of a number of diseases in animals, including fowl cholera. P. multocida strains simultaneously express two lipopolysaccharide (LPS) glycoforms (glycoforms A and B) that differ only in their inner core structure. Glycoform A contains a single 3-deoxy-d-manno-octulosonic acid (Kdo) residue that is phosphorylated by the Kdo kinase, KdkA, whereas glycoform B contains two unphosphorylated Kdo residues. We have previously shown that P. multocida mutants lacking the heptosyltransferase, HptA, produce full-length glycoform B LPS and a large amount of truncated glycoform A LPS, as they cannot add heptose to the glycoform A inner core. These hptA mutants were attenuated in chickens because the truncated LPS made them vulnerable to host defense mechanisms, including antimicrobial peptides. However, here we show that birds inoculated with high doses of the hptA mutant developed fowl cholera and the P. multocida isolates recovered from diseased birds no longer expressed truncated LPS. Sequencing analysis revealed that the in vivo-derived isolates had mutations in kdkA, thereby suppressing the production of glycoform A LPS. Interestingly, a number of the spontaneous KdkA mutant strains produced KdkA with a single amino acid substitution (A112V, R123P, H168Y, or D193N). LPS structural analysis showed that complementation of a P. multocida kdkA mutant with wild-type kdkA restored expression of glycoform A to wild-type levels, whereas complementation with any of the mutated kdkA genes did not. We conclude that in P. multocida KdkA, the amino acids A112, R123, H168, and D193 are critical for Kdo kinase function and therefore for glycoform A LPS assembly.


2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Alfonso Lopez Rodriguez ◽  
Anna Catharina Berge ◽  
Cliff Ramage ◽  
Ryan Saltzman ◽  
Rickie J. Domangue ◽  
...  

Abstract Background The efficacy of a water soluble formulation of tylvalosin (Aivlosin® 625 mg/g granules) was evaluated in the treatment and metaphylaxis of Enzootic Pneumonia (EP) in pigs. In all four trials, pigs in the tylvalosin group were administered 10 mg tylvalosin/kg bodyweight in drinking water daily for 5 consecutive days (TVN). In a single-challenge study, pigs were inoculated with lung homogenate containing Mycoplasma hyopneumoniae. In a dual challenge study, pigs were sequentially inoculated with pure culture of M. hyopneumoniae and Pasteurella multocida. Efficacy was evaluated based on reduction of lung lesions compared to unmedicated control pigs (CTL). In two field studies at European commercial farms with confirmed outbreaks of EP, treatment efficacy in clinically affected fatteners was evaluated based on improved clinical conditions compared to pigs treated with tylosin at 10 mg/kg by injection for 3 consecutive days (TYL). In these field trials, healthy in contact pigs were enrolled for metaphylaxis efficacy evaluation based on reduction in incidence of new clinical cases of respiratory disease compared to unmedicated pigs (CTL). Results In the M. hyopneumoniae-only challenge study, pigs in TVN group had lower lung lesion scores than CTL (6.52 vs. 14.97; p <  0.001). In the dual challenge study with M. hyopneumoniae and P. multocida, pigs in TVN group had lower lung lesion scores than CTL (3.32 vs. 8.37; p <  0.01) and the recovery of both challenge bacteria from the lungs was lower in TVN compared with CTL group (p <  0.01). In field outbreaks of EP, multicentre analysis showed that 13 days after the start of medication, treatment success for TVN pigs was significantly better than for TYL pigs (80.0% vs 48.7% p = 0.03) and metaphylactic administration of TVN significantly reduced the incidence of new clinical cases (2.1% vs. 7.8%; p <  0.01) compared with unmedicated controls. Conclusions Tylvalosin at 10 mg/kg daily for 5 days in drinking water was safe and effective in the treatment and metaphylaxis of EP in pigs associated with infections of M. hyopneumoniae either alone or in combination with P. multocida under both experimental challenge and field natural infection conditions.


Sign in / Sign up

Export Citation Format

Share Document